vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and EAGLE MATERIALS INC (EXP). Click either name above to swap in a different company.

EAGLE MATERIALS INC is the larger business by last-quarter revenue ($556.0M vs $487.7M, roughly 1.1× CLOVER HEALTH INVESTMENTS, CORP.). EAGLE MATERIALS INC runs the higher net margin — 18.5% vs -10.1%, a 28.6% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -0.4%). EAGLE MATERIALS INC produced more free cash flow last quarter ($60.8M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 8.0%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Eagle Materials Inc. is an American producer of building materials based in Dallas, Texas. The company produces cement, concrete, construction aggregate, gypsum, wallboard, paperboard, and sand for hydraulic fracturing.

CLOV vs EXP — Head-to-Head

Bigger by revenue
EXP
EXP
1.1× larger
EXP
$556.0M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+45.1% gap
CLOV
44.7%
-0.4%
EXP
Higher net margin
EXP
EXP
28.6% more per $
EXP
18.5%
-10.1%
CLOV
More free cash flow
EXP
EXP
$129.7M more FCF
EXP
$60.8M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
8.0%
EXP

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
CLOV
CLOV
EXP
EXP
Revenue
$487.7M
$556.0M
Net Profit
$-49.3M
$102.9M
Gross Margin
28.9%
Operating Margin
-10.1%
Net Margin
-10.1%
18.5%
Revenue YoY
44.7%
-0.4%
Net Profit YoY
-123.2%
-13.9%
EPS (diluted)
$3.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
EXP
EXP
Q4 25
$487.7M
$556.0M
Q3 25
$496.6M
$638.9M
Q2 25
$477.6M
$634.7M
Q1 25
$462.3M
$470.2M
Q4 24
$337.0M
$558.0M
Q3 24
$331.0M
$623.6M
Q2 24
$356.3M
$608.7M
Q1 24
$346.9M
$476.7M
Net Profit
CLOV
CLOV
EXP
EXP
Q4 25
$-49.3M
$102.9M
Q3 25
$-24.4M
$137.4M
Q2 25
$-10.6M
$123.4M
Q1 25
$-1.3M
$66.5M
Q4 24
$-22.1M
$119.6M
Q3 24
$-9.2M
$143.5M
Q2 24
$7.4M
$133.8M
Q1 24
$-19.2M
$77.1M
Gross Margin
CLOV
CLOV
EXP
EXP
Q4 25
28.9%
Q3 25
31.3%
Q2 25
29.2%
Q1 25
22.2%
Q4 24
31.9%
Q3 24
24.5%
32.7%
Q2 24
30.3%
30.7%
Q1 24
23.6%
25.1%
Operating Margin
CLOV
CLOV
EXP
EXP
Q4 25
-10.1%
Q3 25
-4.9%
Q2 25
-2.2%
Q1 25
-0.3%
Q4 24
-6.4%
32.8%
Q3 24
-2.7%
34.2%
Q2 24
2.0%
32.0%
Q1 24
-6.5%
26.9%
Net Margin
CLOV
CLOV
EXP
EXP
Q4 25
-10.1%
18.5%
Q3 25
-4.9%
21.5%
Q2 25
-2.2%
19.4%
Q1 25
-0.3%
14.1%
Q4 24
-6.6%
21.4%
Q3 24
-2.8%
23.0%
Q2 24
2.1%
22.0%
Q1 24
-5.5%
16.2%
EPS (diluted)
CLOV
CLOV
EXP
EXP
Q4 25
$3.22
Q3 25
$4.23
Q2 25
$3.76
Q1 25
$2.01
Q4 24
$3.56
Q3 24
$4.26
Q2 24
$3.94
Q1 24
$2.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
EXP
EXP
Cash + ST InvestmentsLiquidity on hand
$78.3M
$419.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$1.5B
Total Assets
$541.0M
$3.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
EXP
EXP
Q4 25
$78.3M
$419.0M
Q3 25
$35.0M
Q2 25
$59.7M
Q1 25
$20.4M
Q4 24
$194.5M
$31.2M
Q3 24
$288.0M
$93.9M
Q2 24
$254.8M
$46.5M
Q1 24
$208.3M
$34.9M
Total Debt
CLOV
CLOV
EXP
EXP
Q4 25
Q3 25
Q2 25
Q1 25
$1.2B
Q4 24
Q3 24
Q2 24
Q1 24
$1.1B
Stockholders' Equity
CLOV
CLOV
EXP
EXP
Q4 25
$308.7M
$1.5B
Q3 25
$340.9M
$1.5B
Q2 25
$344.2M
$1.5B
Q1 25
$336.1M
$1.5B
Q4 24
$341.1M
$1.5B
Q3 24
$342.2M
$1.4B
Q2 24
$324.9M
$1.4B
Q1 24
$292.5M
$1.3B
Total Assets
CLOV
CLOV
EXP
EXP
Q4 25
$541.0M
$3.8B
Q3 25
$559.7M
$3.4B
Q2 25
$575.0M
$3.4B
Q1 25
$583.7M
$3.3B
Q4 24
$580.7M
$3.0B
Q3 24
$653.0M
$3.1B
Q2 24
$674.2M
$3.0B
Q1 24
$671.8M
$2.9B
Debt / Equity
CLOV
CLOV
EXP
EXP
Q4 25
Q3 25
Q2 25
Q1 25
0.86×
Q4 24
Q3 24
Q2 24
Q1 24
0.84×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
EXP
EXP
Operating Cash FlowLast quarter
$-66.9M
$170.8M
Free Cash FlowOCF − Capex
$-69.0M
$60.8M
FCF MarginFCF / Revenue
-14.1%
10.9%
Capex IntensityCapex / Revenue
0.4%
19.8%
Cash ConversionOCF / Net Profit
1.66×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$231.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
EXP
EXP
Q4 25
$-66.9M
$170.8M
Q3 25
$12.1M
$204.6M
Q2 25
$5.4M
$136.6M
Q1 25
$-16.3M
$62.8M
Q4 24
$34.8M
$119.9M
Q3 24
$50.0M
$233.3M
Q2 24
$44.8M
$132.6M
Q1 24
$25.9M
$63.4M
Free Cash Flow
CLOV
CLOV
EXP
EXP
Q4 25
$-69.0M
$60.8M
Q3 25
$11.4M
$96.1M
Q2 25
$4.8M
$60.5M
Q1 25
$-16.5M
$14.5M
Q4 24
$33.3M
$72.5M
Q3 24
$49.6M
$166.8M
Q2 24
$44.4M
$99.5M
Q1 24
$25.5M
$30.9M
FCF Margin
CLOV
CLOV
EXP
EXP
Q4 25
-14.1%
10.9%
Q3 25
2.3%
15.0%
Q2 25
1.0%
9.5%
Q1 25
-3.6%
3.1%
Q4 24
9.9%
13.0%
Q3 24
15.0%
26.7%
Q2 24
12.5%
16.3%
Q1 24
7.3%
6.5%
Capex Intensity
CLOV
CLOV
EXP
EXP
Q4 25
0.4%
19.8%
Q3 25
0.1%
17.0%
Q2 25
0.1%
12.0%
Q1 25
0.0%
10.3%
Q4 24
0.5%
8.5%
Q3 24
0.1%
10.7%
Q2 24
0.1%
5.4%
Q1 24
0.1%
6.8%
Cash Conversion
CLOV
CLOV
EXP
EXP
Q4 25
1.66×
Q3 25
1.49×
Q2 25
1.11×
Q1 25
0.94×
Q4 24
1.00×
Q3 24
1.63×
Q2 24
6.04×
0.99×
Q1 24
0.82×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

EXP
EXP

External Customers$283.5M51%
Gypsum Wallboard$175.9M32%
Recycled Paperboard$47.8M9%
Corporate Joint Venture$29.4M5%
Other$11.8M2%
Western Pennsylvania Acquisition$7.6M1%

Related Comparisons